摘要
背景:国际癌症研究机构(InternationalAgency For CancerResearch)的最新数据显示,乳腺癌是女性癌症的主要发源地,也是女性癌症的主要死因。活性氧(ROS)的诱导和氧化应激是由于氧化原和抗氧化剂之间的平衡受损而引起的,提示ROS和氧化应激参与了乳腺癌的诱导和发展。与正常细胞相比,癌细胞表现出更高水平的活性氧。然而,抗氧化防御的增加,平衡了癌细胞内的氧化状态,表明高水平的活性氧可能通过各种机制阻止肿瘤的发生。ROS和氧化应激在乳腺癌中的这些相互矛盾的作用使科学家们研究了潜在的氧化应激调节剂作为抗癌策略。结论:本文就乳腺癌细胞ROS产生的机制、氧化损伤状态的作用以及引入氧化应激调节剂在乳腺癌治疗策略中的作用进行了综述。这篇综述更多地集中在褪黑素上,这是我们在过去十年中一直在研究的。根据文献,我们的数据表明褪黑素在乳腺癌预防和辅助治疗中具有重要作用。
关键词: 氧化应激,活性氧,乳腺癌,氧化应激调节剂,褪黑素。
Current Medicinal Chemistry
Title:The Role of Oxidative Stress Modulators in Breast Cancer
Volume: 25 Issue: 33
关键词: 氧化应激,活性氧,乳腺癌,氧化应激调节剂,褪黑素。
摘要: Background: Latest data from International Agency for Cancer Research shows that breast cancer is the leading cancer site in women and is the leading cause of death among female cancers. Induction of reactive oxygen species (ROS) and oxidative stress as a consequence of impaired balance between prooxidants and antioxidants are suggested to be involved in induction and progression of breast cancer. Cancer cells are found to exhibit higher levels of ROS compared to normal cells. However increased antioxidant defence which balances the oxidative status within the cancer cells suggests that high ROS levels may prevent tumorigenesis via various mechanisms. These contradictory roles of ROS and oxidative stress in breast cancer let scientists investigate potential oxidative stress modulators as anticancer strategies.
Conclusions: In the present review we address the mechanisms of ROS production in breast cancer cells, the role of impaired oxidative status as well as the benefits of introducing oxidative stress modulators in therapeutic strategies in breast cancer. This review is focusing more on melatonin which we have been working on during the last decade. Our data, in accordance with the literature, suggest an important role for melatonin in breast cancer prevention and adjuvant therapy.
Export Options
About this article
Cite this article as:
The Role of Oxidative Stress Modulators in Breast Cancer, Current Medicinal Chemistry 2018; 25 (33) . https://dx.doi.org/10.2174/0929867324666170711114336
DOI https://dx.doi.org/10.2174/0929867324666170711114336 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Adenoviral Vectors for Cancer Gene Therapy
Current Genomics Meaning Centered Psychotherapy: The State of the Art
Current Psychiatry Reviews Preparation, characterization and <i>in vitro</i> release of zein-pectin capsules for target delivery
Current Drug Delivery Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Current Molecular Medicine Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets TSC-22 (TGF-β Stimulated Clone-22): A Novel Molecular Target for Differentiation-Inducing Therapy in Salivary Gland Cancer
Current Cancer Drug Targets Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design Graphical Abstracts
Current Drug Delivery Imaging Intraductal Carcinoma
Current Cancer Therapy Reviews Cytokines in the Management of High Risk or Advanced Breast Cancer: An Update and Expectation
Current Cancer Drug Targets ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Genomic Instability and Cancer
Current Molecular Medicine Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Oleacein. Translation from Mediterranean Diet to Potential Antiatherosclerotic Drug
Current Pharmaceutical Design From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genistein Inhibits Cell Growth and Invasion Through Regulation of miR-27a in Pancreatic Cancer Cells
Current Pharmaceutical Design PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry